DWT
ALNY icon

Dorsey & Whitney Trust’s Alnylam Pharmaceuticals ALNY Stock Holding History

Dorsey & Whitney Trust’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-460
Closed -$210K – 703
2025
Q3 		$210K Buy
+460
New +$187K 0.01% 652

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Dorsey & Whitney Trust's ALNY Position: Q4 2025 in Review

Dorsey & Whitney Trust sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2025, closing a stake of 460 shares — an estimated $210K sold.

Dorsey & Whitney Trust first reported a position in ALNY in Q3 2025 and held it in 1 quarter. The position peaked at $210K in Q3 2025. 851 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

  • Dorsey & Whitney Trust reported no remaining Alnylam Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Dorsey & Whitney Trust sold 460 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $210K.
  • Dorsey & Whitney Trust first reported a position in Alnylam Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Dorsey & Whitney Trust's Alnylam Pharmaceuticals position peaked at $210K in Q3 2025.
  • 851 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on Dorsey & Whitney Trust's 13F filing for Q4 2025, filed 11 Feb 2026.